Certain individualssuch as those with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2should not use GLP-1 receptor agonists
They are made by different companies (Innovent Biologics and Eli Lilly, respectively), have different clinical trial programs, and produce different levels of weight loss
Assuming the $50 million ZAVA contribution is split across H2 as $23 million in Q3 and $27 million in Q4, the implied organic guidance for Q3 is between $548 million and $568 million
"They're clearly on patients' minds, and that's worth paying attention to," says Sehgal
What the Research Actually Supports The clinical trials that led to FDA approval of semaglutide and tirzepatide used the standard titration schedules
The key is simple but critical: Every weight-loss or health plan must be tailored to each person